Rtw Investments Adds $11M in Fulgent Genetics, Inc. ($FLGT)
RTW Investments boosted its position in FLGT by 83%, now holding 1.29 million shares.
Key Points
- RTW Investments increased its stake in FLGT by 83%, adding 583,973 shares to hold a total of 1.29 million shares valued at $24.1 million.
- FLGT shares are trading near $18.68; the stock has seen various institutional movements, with BlackRock reducing its position by 187,715 shares.
- Insiders at FLGT, including executives, have recently sold shares, and analysts like Piper Sandler have reiterated a 'hold' rating with a $15 price target.
RTW Investments has significantly boosted its stake in FLGT, according to the latest Form 13F filing with the SEC. The firm increased its holdings by 83%, adding 583,973 shares to bring its total to 1.29 million shares. This position is valued at approximately $24.1 million as of the reporting period.
What Changed in RTW Investments' FLGT Position
RTW Investments made a notable move by increasing its stake in FLGT from 705,027 shares to 1,289,000 shares. The addition of 583,973 shares represents an 83% increase in their holdings. This change reflects a significant vote of confidence in the company, with the total value of the position now around $24.1 million.
Other Institutional Activity in FLGT
Several other institutional investors also adjusted their positions in FLGT. BlackRock, Inc. reduced its holdings by 187,715 shares, ending with 2,774,519 shares worth about $44.1 million. Acadian Asset Management LLC grew its position by 48,061 shares to hold 1,233,951 shares valued at $19.6 million. Vanguard Capital Management LLC established a new position with 880,150 shares valued at $13.99 million. Meanwhile, Dimensional Fund Advisors LP trimmed its holdings by 217,348 shares, leaving it with 671,664 shares worth $10.7 million.
FLGT Stock Snapshot
Shares of FLGT are currently trading near $18.68. The stock's performance has been observed by various institutional investors as they adjust their positions. The company's market dynamics continue to attract attention from both large and small investors.
Insider Buying and Selling at Fulgent Genetics, Inc.
Recent insider transactions at FLGT include several sales by company executives. On June 2, 2026, Chief Scientific Officer Hanlin Gao sold 1,688 shares at $17.89, and President and COO Jian Xie sold 2,146 shares at the same price. On June 1, 2026, CFO and Treasurer Paul Kim and CEO Ming Hsieh each sold shares at $18.09, with Kim selling 2,087 shares and Hsieh selling 4,392 shares. These transactions were not part of pre-planned trading programs.
Analysts Set New Price Targets
Analysts have been active in updating their views on FLGT. On May 5, 2026, Piper Sandler reiterated a 'hold' rating with a price target of $15. UBS previously upgraded the stock to a 'buy' rating with a $30 target on August 5, 2025. The analyst consensus remains cautious, with a mixed outlook on the stock's future performance.
Bottom Line
RTW Investments' substantial increase in its FLGT holdings signals a strong belief in the company's potential. While 13F filings provide a snapshot of past holdings, they are a valuable tool for investors tracking institutional confidence in a stock. As always, investors should consider a wide range of factors when evaluating their own positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.